361 related articles for article (PubMed ID: 33292199)
1. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
3. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
5. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
6. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
Liu J; Ji C; Wang Y; Zhang C; Zhu H
Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
[TBL] [Abstract][Full Text] [Related]
7. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma.
Wang Y; Ren F; Song Z; Wang X; Ma X
J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522
[TBL] [Abstract][Full Text] [Related]
8. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
Niu L; Wu Z
Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma.
Wang T; Ji M; Liu W; Sun J
Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625
[TBL] [Abstract][Full Text] [Related]
11. Identification of the prognostic value of a 2-gene signature of the WNT gene family in UCEC using bioinformatics and real-world data.
Hu Y; Zheng M; Zhang D; Gou R; Liu O; Wang S; Lin B
Cancer Cell Int; 2021 Sep; 21(1):516. PubMed ID: 34565373
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy.
Liu J; Wang Y; Mei J; Nie S; Zhang Y
Front Cell Dev Biol; 2021; 9():671736. PubMed ID: 34368124
[TBL] [Abstract][Full Text] [Related]
13. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.
Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG
Biochem Genet; 2023 Dec; ():. PubMed ID: 38108937
[TBL] [Abstract][Full Text] [Related]
14. A novel cuproptosis-related gene signature for overall survival prediction in uterine corpus endometrial carcinoma (UCEC).
Lin S; Xu Y; Liu B; Zheng L; Cao C; Wu P; Ding W; Ren F
Heliyon; 2023 Apr; 9(4):e14613. PubMed ID: 37035374
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
16. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer.
Li J; Xu W; Zhu Y
Oncol Lett; 2020 Nov; 20(5):255. PubMed ID: 32994818
[TBL] [Abstract][Full Text] [Related]
17. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
18. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
[TBL] [Abstract][Full Text] [Related]
19. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
Front Oncol; 2022; 12():923641. PubMed ID: 35719911
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Prognosis and Immune Landscapes Based on Lipid-Metabolism- and Ferroptosis-Associated Signature in Uterine Corpus Endometrial Carcinoma.
Yang P; Lu J; Zhang P; Zhang S
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
